Address: 318 WFM 544, Suite A2, Murphy, TX 75094 Phone: +1 469-782-0165 Useful Resources: Professional Guidelines & Research American Diabetes Association (ADA) Standards of Care : ADA Professional Guidelines FDA Drug Safety Communication GLP-1 Agonists : FDA Safety Information JAMA Network Open Study GLP-1 and Cancer Risk : Original Research Article American Society of Clinical Oncology (ASCO) : Cancer Prevention Guidelines Patient Education Resources American Cancer Society Obesity and Cancer Risk : ACS Obesity Information National Institute of Diabetes and Digestive and Kidney Diseases : NIDDK GLP-1 Information Novo Nordisk Patient Resources : Official Ozempic Information CDC Diabetes Prevention Program : CDC DPP Resources Clinical Decision Support UpToDate GLP-1 Receptor Agonists : Clinical Decision Support Prescribers Digital Reference (PDR) : Drug Information Database American Association of Clinical Endocrinologists : AACE Clinical Guidelines Cancer Screening Guidelines U.S
Visit the FDA website for Form 483
Documentation Summary for CDI Obesity Encounter Checklist For additional guidance on obesity coding, refer to the FY2026 ICD-10-CM Official Guidelines (CMS), the AHA Coding Clinic, and the American Society for Metabolic and Bariatric Surgery (ASMBS) clinical guidelines
Each plan integrates smart nutrition, lab insights, and expert coaching, helping you lose weight effectively and sustain results long-term through evidence-based care
Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene
Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis
